Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02460289 · ClinicalTrials.gov registry record · NA
Minoxidil 5% / Botanical Hair Regimen in Men With Thinning Hair and Male Pattern Hair Loss/Androgenic Alopecia
A NA study of Male Pattern of Hair Loss, Androgenic Alopecia, sponsored by Galderma R&D.
- Completed
- Registry status
- NA
- Development phase
- 63
- Enrollment target
- 1
- Study location
NCT02460289: Completed NA study of Male Pattern of Hair Loss, Androgenic Alopecia, sponsored by Galderma R&D.
NCT02460289 is a NA study of Male Pattern of Hair Loss, Androgenic Alopecia that has completed, run by Galderma R&D. The registered enrollment target is 63 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02460289, a NA study of Male Pattern of Hair Loss, Androgenic Alopecia, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- NA
- Development phase
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to characterize the effect of Minoxidil 5% Foam and Botanical Hair Solution Regimen in men with thinning hair and male pattern hair loss/androgenic alopecia (Norwood III \& IV).
Primary Outcome
The Investigator or a trained grader rated each participant's standardized global photographs for improvement from baseline for parameters like hair thinning, hair growth, impression of scalp hair coverage and overall perception of treatment benefit using a 1-to-7-point Likert scale. Investigator global photograph rating were assessed using 7-point Likert scale. Each score on the individual scale ranged from 1 (minimum) to 7 (maximum), that is, (1) Entirely Disagree; (2) Mostly Disagree; (3) Som
Conditions Studied
Interventions
- DRUG Treatment: Minoxidil 5% / Botanical Hair Solution for Men
Study Locations (1)
Texas
- Stephens & Associates - Richardson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2015-05-19 |
| Est. Completion | 2015-11 |
| Phase | NA |
What the finished NCT02460289 record still lists
NCT02460289 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Male Pattern of Hair Loss, Androgenic Alopecia appearing as the primary indexed condition, and to 1 intervention - of which Treatment: Minoxidil 5% / Botanical Hair Solution for Men is the first listed.
NCT02460289 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02460289 about?
NCT02460289 is a clinical study titled "Minoxidil 5% / Botanical Hair Regimen in Men With Thinning Hair and Male Pattern Hair Loss/Androgenic Alopecia". The purpose of this study is to characterize the effect of Minoxidil 5% Foam and Botanical Hair Solution Regimen in men with thinning hair and male pattern hair loss/androgenic alopecia (Norwood III \& IV).
What is the current status of trial NCT02460289?
This trial is currently completed. It is a NA study. The enrollment target is 63 participants. The study started on 2015-05-19. Estimated completion is 2015-11.
What conditions does trial NCT02460289 study?
This clinical trial studies the following conditions: Male Pattern of Hair Loss, Androgenic Alopecia.
What interventions are being tested in trial NCT02460289?
The interventions under investigation include: Treatment: Minoxidil 5% / Botanical Hair Solution for Men (DRUG).
Who is sponsoring clinical trial NCT02460289?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02460289 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02460289's enrollment target sits among peer trials
63 1157th of 2000 higher than 844 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI